CAR-T Advances, CRISPR Innovation, and Sickle Cell
Kilder
- fiercebiotech.com: Lilly picks up another in vivo CAR-T company with Kelonia buyout worth up to $7B - Fierce Biotech
- biospace.com: Lilly adds gene delivery technology to CAR T in up to $7B Kelonia deal - BioSpace
- bioworld.com: Pleased to own ya, Kelonia: Lilly’s $7B CAR T deal - BioWorld News
- Nature: Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial - Nature
- nature.com: Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial - Nature
- news.google.com: Cilta-Cel Generates 100% ORR, MRD-Negativity Rate in High-Risk Smoldering Myeloma - OncLive
- news-medical.net: Single CAR T infusion shows strong response in patients with high-risk smoldering multiple myeloma - News-Medical
- Bioworld: CRISPR and XIST silence one chromosome 21 copy in Down syndrome - BioWorld News
- bioworld.com: CRISPR and XIST silence one chromosome 21 copy in Down syndrome - BioWorld News
- labroots.com: Scientists Develop a Tool to Silence the Down's Syndrome Chromosome - Labroots
- Biospace: Novo’s late-stage sickle cell win piles pressure on competitors - BioSpace
- biospace.com: Novo’s late-stage sickle cell win piles pressure on competitors - BioSpace
- Statnews: Extended use of Nektar Therapeutics drug shows promise in alopecia - statnews.com
- statnews.com: Extended use of Nektar Therapeutics drug shows promise in alopecia - statnews.com
- news.google.com: Nektar surges again as alopecia drug shows new promise in extension study - BioPharma Dive
- raps.org: Recon: Lilly to acquire Kelonia for up to $7B; Trump issues order to speed psychedelic drug access - RAPS.org
- Fiercebiotech: AstraZeneca’s faith in IL-33 inhibitor continues to pay off with latest phase 3 COPD win - Fierce Biotech
- fiercebiotech.com: AstraZeneca’s faith in IL-33 inhibitor continues to pay off with latest phase 3 COPD win - Fierce Biotech
- wikimedia: Photo by May A Alsayb / Wikimedia Commons / CC BY 4.0
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.